Pigmented purpuric dermatosis refers to one of the three major classes of skin conditions characterized by purpuric skin eruptions. Pigmented purpuric dermatosis are distinguished from other purpura by size (0.3–1 cm) and are most often seen in the lower extremities. : 829   Pigmentary purpuric eruptions may present with one of several clinical patterns. There may be overlapping characteristics among pigmented purpuric dermatosis and between their signs and those of other purpuric eruptions. : 829   Examples of the pigmented purpuric dermatosis group include:: 829–30 
Schambergs disease
Majocchis disease (Purpura annularis telangiectodes)
Gougerot-Blum syndrome (Pigmented purpuric lichenoid dermatitis)
Ducas and Kapetanakis pigmented purpura
Lichen aureusAlthough vascular damage may be present, it is insufficient for these conditions to be considered forms of vasculitis.A few very small non-blinded studies of treatment with narrow-band ultraviolet light have been reported as promising. See also
Purpura
Skin lesion
List of cutaneous conditions

References


== External links ==
Abametapir, sold under the brand name Xeglyze, is a medication used for the treatment of head lice infestation in people six months of age and older.The most common side effects include skin redness, rash, skin burning sensation, skin inflammation, vomiting, eye irritation, skin itching, and hair color changes.Abametapir is a metalloproteinase inhibitor. Abametapir was approved for medical use in the United States in July 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Medical uses
Abametapir is indicated for the topical treatment of head lice infestation in people six months of age and older. Contraindications
Abametapir has no contraindications according to the labeling. Adverse effects
Common adverse effects are burning skin sensations (in 3% of patients), contact dermatitis (2%), skin redness (4%), rash (3%), and vomiting (2%). Interactions
Abametapir blocks the liver enzymes CYP3A4, CYP2B6 and CYP1A2 in vitro. A single application of the drug may lead to increased blood concentrations of drugs that are metabolized by these enzymes. Pharmacology
Mechanism of action
The drug inhibits enzymes called metalloproteinases. In lice, these enzymes play a role in egg development and survival; and consequently, blocking them will disrupt the lices life cycle. Pharmacokinetics
After application to the scalp, part of the substance reaches the bloodstream, where most of it (91.3–92.3%) is bound to plasma proteins. It is metabolized primarily by the liver enzyme CYP1A2 to abametapir hydroxyl and further to abametapir carboxyl (see structure drawings).